Federica Draghi It is not just the daughter of Mario Draghi. Certainly the judgment on her is affected by the fact that her father is one of the most famous economists in the world, as well as former president of the Italian Council and former number one of the ECB, among a thousand other titles.
Just two years after the Foundation, Xgen Venture Sgr Spathe savings management company created by Federica Draghi together with Paolo Fondarò and Thimaty Daniele Scarinci, however, closed 2024 with the first useful millionaire.
The XGEN VENTURE SGR balance sheet
The budget approved shows a net profit of 1,122,389 eurostherefore in very strong growth compared to the 628,708 euros of the previous year.
And the most significant data concerns the overall collection Of 174.2 million euros Reached with the final closing of the main “Xgen Venture Life Science Fund” Final and the parallel fund (formalized on December 6, 2024). The capitals, largely coming from institutional and family office investors, are intended for the financing of startups and innovative SMEs in the biomedical sector, with focus on advanced therapies, medical devices and diagnostics.
Who is Federica Draghi
The biomedical sector, on the other hand, is the one in which Federica Draghi juggles, being graduate in Biology to the Sapienza of Rome and having obtained a doctorate in biochemistry, followed by a Master in Business Administration At the Columbia Business School in New York. After the studies, he became researcher In Cambridge and then, in 2006, it was taken by the Biotechnological Society Genextra based in Milan. This was the trampoline in the sector.
The investment model
During 2024, the Fund made four initial investments in high -tech companies:
- Tes Pharma Srl (Italy);
- Gencepire srl (Italy);
- Protembis GmbH (Germany);
- BV IOCONTURE (Netherlands).
The minimum common denominator of these realities was to be Early-Stage enterprises with solid scientific and potential bases of growth international.
Xgen Venture Sgr, a company in which Mario Draghi’s daughter works, is 100% controlled by Xgen Partners, a vehicle company participated in joint shares by the three founders. Returning to the remuneration of the members -manger, which amount to a total of 1.1 million euros, 904,000 euros are paid directly by the SGR while 200,000 euros They come from the control holding holding holding hold
The commissions net collected by the company went up to 4,185,725 euros, compared to 2.93 million in 2023, reflecting the increase in managed masses and the success of the investment strategy.
The company presents itself as a SGR, (savings management company). It was founded in 2021 by the previous Genextra team, with over 15 years of activity behind them and a significant experience in the startup process, in the discovery and development of innovative solutions for highly dissatisfied medical needs. The Xgen Venture Life Science Fund fund was launched at the end of 2022 and continues to provide advice to the Genextra board of directors for the management of its wallet.
Tax credit
The budget also emerges a tax credit of 54,251 euros boasted by Xgen Partners against the Treasury, due to excess payments relating to IRES and IRAP in 2024, which will be brought into compensation in 2025. According to estimates, even 2025 could lead to excellent results.
